Stockscreener 앱 받기
6.04
5.63%
-0.36
전일 마감가:
$6.40
열려 있는:
$6.33
하루 거래량:
57,289
Relative Volume:
0.30
시가총액:
$428.08M
수익:
-
순이익/손실:
$-159.39M
주가수익비율:
-1.7062
EPS:
-3.5401
순현금흐름:
$-105.22M
1주 성능:
-10.52%
1개월 성능:
+1.14%
6개월 성능:
-40.67%
1년 성능:
-56.70%
1일 변동 폭
$6.00
$6.33
1주일 범위
$6.00
$7.05
52주 변동 폭
$4.77
$14.72
Abivax Adr Stock (ABVX) Company Profile
ABVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
6.04 | 428.08M | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | Laidlaw | Buy |
| 2024-05-20 | 개시 | BTIG Research | Buy |
| 2024-04-29 | 개시 | Guggenheim | Buy |
| 2024-04-29 | 개시 | Piper Sandler | Overweight |
| 2023-11-14 | 개시 | Leerink Partners | Outperform |
| 2023-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Abivax Adr 주식(ABVX)의 최신 뉴스
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - GlobeNewswire Inc.
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater
Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater
Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater
Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater
Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire
Abivax Adr (ABVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):